Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)

Conditions

• Abdominopelvic Sarcomas

Eligibility Criteria

Sex

ALL

Age

12 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy — RADIATION
  stereotactic body radiation therapy (SBRT) administered over 5 days x 5.0 - 6.0 Gy for patients with abdominopelvic sarcomas.

Study Details

Recent advances in radiation treatment have allowed for higher doses per treatment to be delivered safely. This study plans to use an MRI-guided linear accelerator to deliver the radiation treatment to ensure that the radiation dose is administered to the cancerous tumor, not the vital body organs. Potential participants with a sarcoma diagnosis will be referred to Radiation Oncology during this study. If the participant is interested in participating in this study, s/he receives radiation treatment daily for 5 consecutive days except for weekends and holidays. Within 12 weeks of completing the radiation therapy, the participant will have the primary tumor surgically removed. The radiation oncology team will follow the patients for 5 years after completing radiation therapy.

Key Dates

Start date

May 30, 2024

Status verified

Jun 2026

Primary completion

May 30, 2027

Completion

May 26, 2028

Study Design

Enrollment

20 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Arm I
  MRI or CT-guided SBRT will be delivered in the pre-operative setting. Patients will receive 5.0-6.0 Gy x 5 fractions delivered daily.

Primary Outcome Measure

Radiation morbidity at 2 years [ Time Frame: At 2 years ]

Central Contacts

• Christy Palodichuk
  3107942971
  [email protected]
• Vincent Basehart
  3102678954
  [email protected]

Locations (1)

Find similar trials in Los Angeles, CA